 LONDON, Jan. 20, 2023 GLOBE NEWSWIRE Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the companys Board of Directors. The companys non-executive Chairman, John H Johnson, who has held the role since September 2021, will not stand for re-election at Autolus upcoming annual shareholder ... The post Autolus Therapeutics announces Board changes appeared first on ForexTV... 